Suchergebnisse - "JAK inhibitor"

PubPharm (122)

1

Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease : a case series and literature review on Janus kinase inhibitors for the disease

enthalten in: Rheumatology international | 2024

von Harada, H. | Shoda, H. | Tsuchiya, H. | +3

2

Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF

enthalten in: Journal of clinical immunology | 2024

von Koh, J. | Kim, D. | Son, S. | +10

3

Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib

enthalten in: Journal of clinical immunology | 2024

von Dotta, L. | Todaro, F. | Baronio, M. | +13

4

Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa : A retrospective case series

enthalten in: The Journal of dermatology | 2024

von Kwon, I. | Kim, S. | Kim, S. | +1

5

Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials

enthalten in: Clinical rheumatology | 2024

von Amer, B. | Afifi, E. | Mouffokes, A. | +3

6

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults : pooled results from 2 phase 3 studies

enthalten in: The Journal of dermatological treatment | 2024

von Simpson, E. | Bissonnette, R. | Chiesa Fuxench, Z. | +4

7

A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment

enthalten in: International immunopharmacology | 2024

von Heidari, A. | Ghane, Y. | Heidari, N. | +2

8

A safety evaluation of ruxolitinib for the treatment of polycythemia vera

enthalten in: Expert opinion on drug safety | 2024

von Boldrini, V. | Vannucchi, A. | Guglielmelli, P.

9

Use of tofacitinib in baricitinib-refractory atopic dermatitis : An example of JAK inhibitor switching

enthalten in: Pediatric dermatology | 2024

von Dhir, B. | Meena, S. | Sardana, K. | +1

10

Response to Papp et al's "Long-term safety and disease control with ruxolitinib cream in atopic dermatitis : Results from two phase 3 studies"

enthalten in: Journal of the American Academy of Dermatology | 2024

von Isaq, N. | Link, J.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]